ArticleMedical mycology case reports2021
Disseminated
Article in Medical mycology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Humans vs. Fungi: An Overview of Fungal Pathogens against Humans.Pathogens (Basel, Switzerland) · 2024Review
- Case Report: Cryptococcal Meningitis in a Previously Immunocompetent Patient with Coronavirus Disease 2019.The American journal of tropical medicine and hygiene · 2024Article
- Case report: Experience and insights on the treatment of two cases of cryptococcal meningitis during the later stages of the COVID-19 pandemic.Frontiers in immunology · 2024Article
- COVID-19 Associated with Cryptococcosis: A New Challenge during the Pandemic.Journal of fungi (Basel, Switzerland) · 2022Review
- Multidistrict Host-Pathogen Interaction during COVID-19 and the Development Post-Infection Chronic Inflammation.Pathogens (Basel, Switzerland) · 2022Review
- COVID-19-associated Cryptococcus infection (CACI): a review of literature and clinical pearls.Infection · 2022Review
- Review
- The Sweet Side of Fungal Infections: Structural Glycan Diversity and Its Importance for Pathogenic Adaptation.Medicines (Basel, Switzerland) · 2022Article
- Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients.Journal of fungi (Basel, Switzerland) · 2022Review
- Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients.Journal of fungi (Basel, Switzerland) · 2022Review
- Exploring SARS-CoV2 host-pathogen interactions and associated fungal infections cross-talk: Screening of targets and understanding pathogenesis.Computational and structural biotechnology journal · 2022Article
- Overview of COVID-19-Associated Invasive Fungal Infection.Current fungal infection reports · 2022Review
- Invasive cryptococcal disease in COVID-19: systematic review of the literature and analysis.Le infezioni in medicina · 2022Review
- Article
- COVID-19 associated with cryptococcosis: a scoping review.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus associated with immune dysregulation. The use of immunosuppressant drugs as part of COVID-19 treatment (such as Tocilizumab or high -dose corticosteroids) increases the risk of opportunistic infections. Here we present a case of a patient without prior immunosuppression that developed a serious fungal infection after the use of high dose corticosteroids in the setting of severe COVID-19 and cryptogenic organizing pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.